Cleared Traditional

K212468 - Tigereye CTO-Crossing Catheter (FDA 510(k) Clearance)

Jan 2022
Decision
153d
Days
Class 2
Risk

K212468 is an FDA 510(k) clearance for the Tigereye CTO-Crossing Catheter. This device is classified as a Catheter For Crossing Total Occlusions (Class II - Special Controls, product code PDU).

Submitted by Avinger, Inc. (Redwood City, US). The FDA issued a Cleared decision on January 6, 2022, 153 days after receiving the submission on August 6, 2021.

This device falls under the Cardiovascular FDA review panel. Regulated under 21 CFR 870.1250. To Facilitate The Intraluminal Placement Of Conventional Guidewires Beyond Stenotic Lesions (including Subchronic And Chronic Total Occlusions) In The Peripheral Vasculature Prior To Further Percutaneous Intervention, Such As Angioplasty, Atherectomy Or Stent Placement..

Submission Details

510(k) Number K212468 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 06, 2021
Decision Date January 06, 2022
Days to Decision 153 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF

Device Classification

Product Code PDU — Catheter For Crossing Total Occlusions
Device Class Class II - Special Controls
CFR Regulation 21 CFR 870.1250
Definition To Facilitate The Intraluminal Placement Of Conventional Guidewires Beyond Stenotic Lesions (including Subchronic And Chronic Total Occlusions) In The Peripheral Vasculature Prior To Further Percutaneous Intervention, Such As Angioplasty, Atherectomy Or Stent Placement.